|
USA-6411-Insurance Azienda Directories
|
Azienda News:
- News and Updates - Breakthrough T1D
Discover type 1 diabetes news from Breakthrough T1D about research, advocacy, initiatives, and our community
- T1D Strong News
Sanofi’s Tzield has been accepted for expedited review in the U S to treat stage 3 type 1 diabetes through the FDA Commissioner’s National Priority Voucher pilot program This landmark event shifts the T1D treatment landscape, placing greater emphasis on early detection and staging
- Type 1 diabetes community celebrates research milestone during National . . .
TrialNet and Breakthrough T1D (formerly JDRF) announced the research milestone as part of National Diabetes Month, observed each November to raise awareness about diabetes and encourage families to take action to protect their health
- Updates in Type 1 Diabetes (T1D): What Recent Findings Might Mean for . . .
Recent articles show the rising population burden of T1D, illustrate current disease‐modifying prevention efforts, and show the growing recognition of interrelationships between T1D and T2D and their implications for complications
- Sanofi’s Tzield accepted for expedited review in the US for stage 3 . . .
Tzield is approved in the US, the UK, China, Canada, Israel, the Kingdom of Saudi Arabia, the United Arab Emirates, and Kuwait to delay the onset of stage 3 T1D in adults and pediatric patients eight years and older diagnosed with stage 2 T1D
- Updates on recent type 1 diabetes clinical trials - Breakthrough T1D
Here we report on recent results from international trials relevant to our type 1 diabetes (T1D) community To see if there is actively recruiting research that you can be part of, see our T1D Clinical Trial Finder
- Breakthrough T1D Kicks Off Fall Walks to Celebrate Community and Raise . . .
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, has kicked off a series of Breakthrough T1D Walks across the country,
- Endocrine Society proposes research efforts to improve treatment . . .
A new Scientific Statement released today by the Endocrine Society highlights potential research directions related to the pathogenesis of type 1 diabetes (T1D) that should help with the development of new and improved treatment options
- We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who . . .
We used administrative claims from 4 sources to identify prevalent and incident T1DM patients in the US, as well as various demographic and insurance characteristics of the patient population
- Press Release: Sanofi’s Tzield accepted for expedited review in the US . . .
Tzield is the first and only disease modifying therapy in autoimmune T1D; it was approved in the US in November 2022 to delay the onset of Stage 3 type 1 diabetes in adults and children eight years and older diagnosed with stage 2 T1D
|
|